cervical pre-cancer
Qiagen, Inovio Expand CDx Partnership, Starting With NGS Test for Cervical Dysplasia Therapy
The partners will develop a test to identify women most likely to benefit from VGX-3100, Inovio's immunotherapy to treat HPV-associated advanced cervical dysplasia.
BD Receives FDA Supplemental Premarket Approval for Extended Genotyping HPV MDx
The expanded test can be used for genotype risk-based patient monitoring to prevent over-treatment, BD has said.
Cervicovaginal Microbiomes of HPV-Infected Women Lead To Potential Pre-Cancer Marker
Profiling microbial communities in cervicovaginal samples from women carrying high-risk HPV strains, researchers found possible markers of pre-cancer progression.
The new test uses the number of sequencing reads at specific early and late HPV transcripts as a biomarker for high-grade cytology.
Qiagen, Inovio to Develop CDx for Immunotherapy Targeting Precancerous Cervical Lesions
The test will guide clinical decision making related to Inovio's DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus.
Jul 8, 2010